EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Stereotactic magnetic resonance imaging-guided adaptive radiotherapy: a pooled analysis of a master prospective trial

Jonathan E Leeman iD, Kee-Young Shin iD, Alexander Droznin iD, Paul Catalano iD, Daniel N Cagney, Lisa Singer, Rasheedat Damilola Oniyangi iD, Kris Zhai iD, Grant Benham, Sejal Chirmade, Jennifer Campbell, Sara Boyle und 24 weitere

JNCI: Journal of the National Cancer Institute · 2025

DOI: 10.1093/jnci/djaf208 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Jonathan E Leeman und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Brigham and Women's Hospital/Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States. Hauptthemen laut MEDLINE: Radiotherapy, Image-Guided, Magnetic Resonance Imaging, Radiosurgery, Neoplasms. Die Arbeit nennt 20 Literaturangaben. Gefördert von: ViewRay and Diana's Fibroid Foundation, ViewRay and Diana’s Fibroid Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Master clinical trial protocol structures offer administrative, procedural, and statistical advantages but have not been applied in assessing new radiotherapy devices. Herein, we report on a pooled analysis from a first-of-kind master trial evaluating stereotactic MRI-guided adaptive radiotherapy (SMART).

Methods

Subjects were enrolled in a prospective master protocol evaluating SMART for multiple oncologic indications. CTCAE v5 toxicities, patient-reported outcome measures (PROMs), and treatment efficiency metrics were assessed across the entire cohort and in anatomic subsets.

Results

One hundred and ninety three subjects were enrolled into 20 sub-protocols for different SMART indications. Data were analyzed from the first 161 subjects. The median time from subprotocol amendment submission to activation was 70.5 days (range: 63-93). All completed phase I sub-protocols (n = 9) met the primary endpoints of safety and feasibility. The risk of grade 3+ toxicity was 1.9% (95% CI 0.4% to 5.3%), 7.1% (95% CI 0.9% to 23.5%), 1.8% (95% CI 0.05% to 9.6%) and 0% (95% CI 0.0% to 4.7%) in the overall cohort and thoracic, abdominal and pelvic subsets, respectively. PROMs (PROMIS-10) during and after SMART were unchanged from baseline in all subsets. SMART delivery efficiency improved over the study period (first vs. final 3 months: 78.5 vs. 48.2 minutes, P < .001). Adaptive planning performed for 771 fractions resulted in clinically significant plan improvements in 93.0% of fractions (52.7% for organ-at-risk sparing, 20.5% for target coverage, and 19.8% for both).

Conclusions

SMART is feasible and safe for multiple thoracic, abdominal and pelvic radiotherapy indications. The master protocol platform offers an adaptable approach for assessment of new oncologic treatment technologies applicable to multiple indications. Clinical Trial NCT04115254.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Radiotherapy, Image-GuidedMagnetic Resonance ImagingRadiosurgeryNeoplasmsHumansProspective StudiesFemaleMaleMiddle AgedAgedAdultAged, 80 and overPatient Reported Outcome MeasuresRadiotherapy Planning, Computer-Assisted

Autor:innen und Institutionen

  • Department of Radiation Oncology, Brigham and Women's Hospital/Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
  • Department of Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.

ORCID-Profile: Jonathan E Leeman, Kee-Young Shin, Alexander Droznin, Paul Catalano, Rasheedat Damilola Oniyangi, Kris Zhai, Christopher L Williams, Zhaohui Han, Atchar Sudhyadhom, Dianne Ferguson, Kamal Singhrao, Shu-Hui Hsu, Neil E Martin, Harvey J Mamon, Ritchell Van Dams, Shyam K Tanguturi, Kelly J Fitzgerald, Hesham Elhalawani, Danielle S Bitterman, Jonathan D Schoenfeld, Paul Nguyen, Daphne A Haas-Kogan, Raymond Mak

Förderung

  • ViewRay and Diana's Fibroid Foundation
  • ViewRay and Diana’s Fibroid Foundation

Zitieren

APA

Leeman, J. E., Shin, K. Y., Droznin, A., Catalano, P., Cagney, D. N., Singer, L., Oniyangi, R. D., Zhai, K., Benham, G., Chirmade, S., Campbell, J., Boyle, S., Saranteas, A., Williams, C. L., Huynh, E., Han, Z., Sudhyadhom, A., Hu, Y. H., Ferguson, D., …, & Mak, R. (2025). Stereotactic magnetic resonance imaging-guided adaptive radiotherapy: a pooled analysis of a master prospective trial. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf208

Vancouver

Leeman JE, Shin KY, Droznin A, Catalano P, Cagney DN, Singer L, et al. Stereotactic magnetic resonance imaging-guided adaptive radiotherapy: a pooled analysis of a master prospective trial. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djaf208

BibTeX
@article{Leeman2025,
  author = {Leeman, Jonathan E and Shin, Kee-Young and Droznin, Alexander and Catalano, Paul and Cagney, Daniel N and Singer, Lisa and Oniyangi, Rasheedat Damilola and Zhai, Kris and Benham, Grant and Chirmade, Sejal and Campbell, Jennifer and Boyle, Sara and Saranteas, Abbie and Williams, Christopher L and Huynh, Elizabeth and Han, Zhaohui and Sudhyadhom, Atchar and Hu, Yue-Houng and Ferguson, Dianne and Singhrao, Kamal and Hsu, Shu-Hui and Bredfeldt, Jeremy and Martin, Neil E and Mancias, Joseph D and Mamon, Harvey J and Van Dams, Ritchell and Venkatachalam, Veena and Tanguturi, Shyam K and Huynh, Mai Anh and Fitzgerald, Kelly J and Elhalawani, Hesham and Bitterman, Danielle S and Schoenfeld, Jonathan D and Nguyen, Paul and Haas-Kogan, Daphne A and Mak, Raymond},
  title = {Stereotactic magnetic resonance imaging-guided adaptive radiotherapy: a pooled analysis of a master prospective trial},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  doi = {10.1093/jnci/djaf208}
}
Kostenlos starten →